Anti-TNF (adalimumab) injection for the treatment of pain-predominant early-stage frozen shoulder: the Anti-Freaze-Feasibility randomised controlled trial

Objective: The Anti-Freaze-F (AFF) trial assessed the feasibility of conducting a definitive trial to determine whether intra-articular injection of adalimumab can reduce pain and improve function in people with pain-predominant early-stage frozen shoulder. Design: Multicentre, randomised feasibilit...

Повний опис

Бібліографічні деталі
Автори: Hopewell, S, Srikesavan, C, Evans, A, Er, F, Rangan, A, Preece, J, Francis, A, Massa, MS, Feldmann, M, Lamb, S, Nanchahal, J
Формат: Journal article
Мова:English
Опубліковано: BMJ Publishing Group 2024
_version_ 1826314822345555968
author Hopewell, S
Srikesavan, C
Evans, A
Er, F
Rangan, A
Preece, J
Francis, A
Massa, MS
Feldmann, M
Lamb, S
Nanchahal, J
author_facet Hopewell, S
Srikesavan, C
Evans, A
Er, F
Rangan, A
Preece, J
Francis, A
Massa, MS
Feldmann, M
Lamb, S
Nanchahal, J
author_sort Hopewell, S
collection OXFORD
description Objective: The Anti-Freaze-F (AFF) trial assessed the feasibility of conducting a definitive trial to determine whether intra-articular injection of adalimumab can reduce pain and improve function in people with pain-predominant early-stage frozen shoulder. Design: Multicentre, randomised feasibility trial, with embedded qualitative study. Setting: Four UK National Health Service (NHS) musculoskeletal and related physiotherapy services. Participants: Adults ≥18 years with new episode of shoulder pain attributable to early-stage frozen shoulder. Interventions: Participants were randomised (centralised computer generated 1:1 allocation) to either ultrasound-guided intra-articular injection of: (1) adalimumab (160 mg) or (2) placebo (saline (0.9% sodium chloride)). Participants and outcome assessors were blinded to treatment allocation. Second injection of allocated treatment (adalimumab 80 mg) or equivalent placebo was administered 2–3 weeks later. Primary feasibility objectives: (1) Ability to screen and identify participants; (2) willingness of eligible participants to consent and be randomised; (3) practicalities of delivering the intervention; (4) SD of the Shoulder Pain and Disability Index (SPADI) score and attrition rate at 3 months. Results: Between 31 May 2022 and 7 February 2023, 156 patients were screened of whom 39 (25%) were eligible. The main reasons for ineligibility were other shoulder disorder (38.5%; n=45/117) or no longer in pain-predominant frozen shoulder (33.3%; n=39/117). Of the 39 eligible patients, nine (23.1%) consented to be randomised (adalimumab n=4; placebo n=5). The main reason patients declined was because they preferred receiving steroid injection (n=13). All participants received treatment as allocated. The mean time from randomisation to first injection was 12.3 (adalimumab) and 7.2 days (placebo). Completion rates for patient-reported and clinician-assessed outcomes were 100%. Conclusion: This study demonstrated that current NHS musculoskeletal physiotherapy settings yielded only small numbers of participants, too few to make a trial viable. This was because many patients had passed the early stage of frozen shoulder or had already formulated a preference for treatment. Trial registration number: ISRCTN 27075727, EudraCT 2021-03509-23, ClinicalTrials.gov NCT05299242 (REC 21/NE/0214).
first_indexed 2024-09-25T04:16:37Z
format Journal article
id oxford-uuid:259f5d71-a365-4c5c-94cb-917f335bcc38
institution University of Oxford
language English
last_indexed 2024-12-09T03:13:54Z
publishDate 2024
publisher BMJ Publishing Group
record_format dspace
spelling oxford-uuid:259f5d71-a365-4c5c-94cb-917f335bcc382024-10-16T09:30:00ZAnti-TNF (adalimumab) injection for the treatment of pain-predominant early-stage frozen shoulder: the Anti-Freaze-Feasibility randomised controlled trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:259f5d71-a365-4c5c-94cb-917f335bcc38EnglishJisc Publications RouterBMJ Publishing Group2024Hopewell, SSrikesavan, CEvans, AEr, FRangan, APreece, JFrancis, AMassa, MSFeldmann, MLamb, SNanchahal, JObjective: The Anti-Freaze-F (AFF) trial assessed the feasibility of conducting a definitive trial to determine whether intra-articular injection of adalimumab can reduce pain and improve function in people with pain-predominant early-stage frozen shoulder. Design: Multicentre, randomised feasibility trial, with embedded qualitative study. Setting: Four UK National Health Service (NHS) musculoskeletal and related physiotherapy services. Participants: Adults ≥18 years with new episode of shoulder pain attributable to early-stage frozen shoulder. Interventions: Participants were randomised (centralised computer generated 1:1 allocation) to either ultrasound-guided intra-articular injection of: (1) adalimumab (160 mg) or (2) placebo (saline (0.9% sodium chloride)). Participants and outcome assessors were blinded to treatment allocation. Second injection of allocated treatment (adalimumab 80 mg) or equivalent placebo was administered 2–3 weeks later. Primary feasibility objectives: (1) Ability to screen and identify participants; (2) willingness of eligible participants to consent and be randomised; (3) practicalities of delivering the intervention; (4) SD of the Shoulder Pain and Disability Index (SPADI) score and attrition rate at 3 months. Results: Between 31 May 2022 and 7 February 2023, 156 patients were screened of whom 39 (25%) were eligible. The main reasons for ineligibility were other shoulder disorder (38.5%; n=45/117) or no longer in pain-predominant frozen shoulder (33.3%; n=39/117). Of the 39 eligible patients, nine (23.1%) consented to be randomised (adalimumab n=4; placebo n=5). The main reason patients declined was because they preferred receiving steroid injection (n=13). All participants received treatment as allocated. The mean time from randomisation to first injection was 12.3 (adalimumab) and 7.2 days (placebo). Completion rates for patient-reported and clinician-assessed outcomes were 100%. Conclusion: This study demonstrated that current NHS musculoskeletal physiotherapy settings yielded only small numbers of participants, too few to make a trial viable. This was because many patients had passed the early stage of frozen shoulder or had already formulated a preference for treatment. Trial registration number: ISRCTN 27075727, EudraCT 2021-03509-23, ClinicalTrials.gov NCT05299242 (REC 21/NE/0214).
spellingShingle Hopewell, S
Srikesavan, C
Evans, A
Er, F
Rangan, A
Preece, J
Francis, A
Massa, MS
Feldmann, M
Lamb, S
Nanchahal, J
Anti-TNF (adalimumab) injection for the treatment of pain-predominant early-stage frozen shoulder: the Anti-Freaze-Feasibility randomised controlled trial
title Anti-TNF (adalimumab) injection for the treatment of pain-predominant early-stage frozen shoulder: the Anti-Freaze-Feasibility randomised controlled trial
title_full Anti-TNF (adalimumab) injection for the treatment of pain-predominant early-stage frozen shoulder: the Anti-Freaze-Feasibility randomised controlled trial
title_fullStr Anti-TNF (adalimumab) injection for the treatment of pain-predominant early-stage frozen shoulder: the Anti-Freaze-Feasibility randomised controlled trial
title_full_unstemmed Anti-TNF (adalimumab) injection for the treatment of pain-predominant early-stage frozen shoulder: the Anti-Freaze-Feasibility randomised controlled trial
title_short Anti-TNF (adalimumab) injection for the treatment of pain-predominant early-stage frozen shoulder: the Anti-Freaze-Feasibility randomised controlled trial
title_sort anti tnf adalimumab injection for the treatment of pain predominant early stage frozen shoulder the anti freaze feasibility randomised controlled trial
work_keys_str_mv AT hopewells antitnfadalimumabinjectionforthetreatmentofpainpredominantearlystagefrozenshouldertheantifreazefeasibilityrandomisedcontrolledtrial
AT srikesavanc antitnfadalimumabinjectionforthetreatmentofpainpredominantearlystagefrozenshouldertheantifreazefeasibilityrandomisedcontrolledtrial
AT evansa antitnfadalimumabinjectionforthetreatmentofpainpredominantearlystagefrozenshouldertheantifreazefeasibilityrandomisedcontrolledtrial
AT erf antitnfadalimumabinjectionforthetreatmentofpainpredominantearlystagefrozenshouldertheantifreazefeasibilityrandomisedcontrolledtrial
AT rangana antitnfadalimumabinjectionforthetreatmentofpainpredominantearlystagefrozenshouldertheantifreazefeasibilityrandomisedcontrolledtrial
AT preecej antitnfadalimumabinjectionforthetreatmentofpainpredominantearlystagefrozenshouldertheantifreazefeasibilityrandomisedcontrolledtrial
AT francisa antitnfadalimumabinjectionforthetreatmentofpainpredominantearlystagefrozenshouldertheantifreazefeasibilityrandomisedcontrolledtrial
AT massams antitnfadalimumabinjectionforthetreatmentofpainpredominantearlystagefrozenshouldertheantifreazefeasibilityrandomisedcontrolledtrial
AT feldmannm antitnfadalimumabinjectionforthetreatmentofpainpredominantearlystagefrozenshouldertheantifreazefeasibilityrandomisedcontrolledtrial
AT lambs antitnfadalimumabinjectionforthetreatmentofpainpredominantearlystagefrozenshouldertheantifreazefeasibilityrandomisedcontrolledtrial
AT nanchahalj antitnfadalimumabinjectionforthetreatmentofpainpredominantearlystagefrozenshouldertheantifreazefeasibilityrandomisedcontrolledtrial